SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments

SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments

IntroductionThe study aims to evaluate the concentration of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike1 protein (S1RBD) in BNT162b2- vaccinated relapsing-remitting multiple sclerosis (RRMS) individuals receiving disease-modifying treatments (DMTs).MethodsSerum from 12...

Full description

Bibliographic Details
Main Authors: Anastasia Lambrianides, Elie Deeba, Maria Hadjiagapiou, Marios Pantzaris, George Krashias, Christina Christodoulou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Neurology
Subjects:
SARS-CoV-2
multiple sclerosis
IgG antibodies
vaccines
disease-modifying treatments
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1092999/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1092999/full

Similar Items